Propranolol XR Shortage: A Provider's Overview

Extended-release Propranolol hydrochloride (Inderal LA, InnoPran XL, and generics) has been subject to intermittent supply disruptions affecting multiple strengths — 60 mg, 80 mg, 120 mg, and 160 mg capsules. As of early 2026, availability remains inconsistent across retail and mail-order pharmacies nationwide.

This article provides a clinical summary of the shortage, therapeutic alternatives, switching considerations, and resources to help you manage affected patients.

Current Shortage Status

The FDA Drug Shortage Database has listed extended-release Propranolol with limited availability from several manufacturers, including Teva, Ani Pharmaceuticals, Heritage Pharmaceuticals, and Par Pharmaceutical. Contributing factors include:

• Manufacturing capacity constraints among key generic producers
• Active pharmaceutical ingredient (API) supply disruptions from overseas suppliers
• Increased prescribing volume, driven in part by expanded off-label use for anxiety, performance anxiety, and PTSD
• Market consolidation reducing the number of ER formulation manufacturers

Availability varies significantly by geography, pharmacy type, and wholesaler relationships. Independent pharmacies with access to secondary wholesalers may have better success sourcing inventory.

Clinical Considerations for Therapeutic Substitution

Immediate-Release Propranolol

The most direct substitution is converting to immediate-release (IR) Propranolol hydrochloride, which remains widely available as a generic. Key considerations:

• Dosing conversion: The total daily dose typically remains the same, divided into 2-4 doses per day. For example, Propranolol ER 80 mg once daily converts to Propranolol IR 20 mg four times daily or 40 mg twice daily.
• Pharmacokinetics: IR Propranolol produces higher peak plasma concentrations (Cmax) with shorter time to peak, which may cause more pronounced side effects (fatigue, bradycardia) in some patients.
• Adherence: Multiple daily dosing reduces adherence. Consider whether your patient population can manage a more complex regimen.

Alternative Beta-Blockers

When Propranolol is unavailable in any form, consider the following alternatives based on indication:

Hypertension

• Metoprolol succinate ER (Toprol XL): Beta-1 selective, once-daily dosing, widely available. First-line alternative for blood pressure management.
• Atenolol: Beta-1 selective, once-daily dosing, very low cost. Renally eliminated — dose adjust in renal impairment.
• Nadolol: Non-selective like Propranolol, once-daily dosing due to long half-life (20-24 hours). May be a closer pharmacologic match.

Migraine Prophylaxis

• Nadolol: Non-selective beta-blocker with evidence for migraine prevention, though not FDA-approved for this indication.
• Timolol: Non-selective beta-blocker with FDA approval for migraine prophylaxis. Less commonly prescribed; verify availability.
• Non-beta-blocker alternatives: Topiramate, Amitriptyline, Venlafaxine, Valproate, or CGRP monoclonal antibodies (Erenumab, Fremanezumab, Galcanezumab) for refractory cases.

Essential Tremor

• Primidone: The primary non-beta-blocker alternative for essential tremor. Can be used alone or in combination.
• Nadolol: Has some evidence for tremor reduction, though less robust than Propranolol.

Performance Anxiety / Situational Anxiety

• IR Propranolol: Typically prescribed as a single 10-40 mg dose taken 30-60 minutes before the event. IR availability should be adequate for this use case.

Switching Protocols and Safety

When transitioning patients off Propranolol XR:

• Do not discontinue abruptly. Beta-blocker withdrawal can precipitate rebound tachycardia, hypertension, and in patients with coronary artery disease, angina or myocardial infarction.
• Cross-taper when switching agents. Gradually reduce Propranolol while titrating the replacement medication over 1-2 weeks.
• Monitor closely during the transition period — check heart rate, blood pressure, and symptom control at appropriate intervals.
• Counsel patients on what to expect during the switch, including potential differences in side effect profile.

Helping Patients Find Propranolol XR

For patients who prefer to remain on Propranolol XR, you can direct them to resources that track pharmacy-level availability:

• MedFinder for Providers — a tool that checks real-time pharmacy stock for specific medications by zip code. You or your staff can use it to identify pharmacies with Propranolol XR in stock before sending the prescription.
• Pharmacy benefit manager (PBM) networks — contact the patient's PBM to identify in-network pharmacies with available inventory.
• Specialty and compounding pharmacies — in rare cases, compounding pharmacies can prepare extended-release Propranolol formulations, though this should be a last resort due to cost and bioequivalence concerns.

Patient Communication Strategies

Proactive communication can reduce patient anxiety and prevent dangerous self-management decisions:

• Inform patients about the shortage before they encounter it at the pharmacy
• Provide written instructions for the alternative medication, including dosing schedule
• Emphasize the importance of not stopping Propranolol abruptly
• Share the patient-facing shortage update and pharmacy search guide as resources

Documentation and Coding

When switching medications due to a shortage, document the clinical rationale in the patient's chart. This protects against prior authorization denials and supports continuity of care if the patient returns to Propranolol XR when supply stabilizes.

Summary

The Propranolol XR shortage in 2026 requires providers to be prepared with alternative treatment strategies. Immediate-release Propranolol remains the most straightforward substitution, while Nadolol offers the closest pharmacologic match for patients requiring a non-selective beta-blocker. Use MedFinder for Providers to help patients locate available stock, and ensure safe transitions with appropriate tapering and monitoring protocols.